Skip to main content
VYNE Therapeutics Inc. logo

VYNE Therapeutics Inc. — Investor Relations & Filings

Ticker · VYNE ISIN · US92941V1008 US Manufacturing
Open in API
Filings indexed 608 across all filing types
Latest filing 2019-06-27 Director's Dealing
Country US United States of America
Listing US VYNE

About VYNE Therapeutics Inc.

https://vynetherapeutics.com/

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company's primary objective is to address unmet medical needs by advancing a pipeline of novel drug candidates. VYNE's approach centers on innovating beyond traditional assumptions to find improved solutions for patients with complex inflammatory and immunological diseases.

Recent filings

Filing Released Lang Actions
FORM 3 SUBMISSION
Director's Dealing
2019-06-27 English
FORM 4 SUBMISSION
Director's Dealing
2019-06-27 English
FORM 4 SUBMISSION
Director's Dealing
2019-06-27 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filing dated June 25, 2019, reporting the submission of matters to a vote of security holders at the company's Annual Meeting. It details the voting results for director elections and auditor ratification. The content focuses on official voting results from the shareholder meeting, not the meeting materials or the full annual report. The document length is 4283 characters, which is relatively short and consistent with a voting results announcement. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2019-06-27 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The key content is under Item 5.02, which relates to the departure of a director or certain officers and appointment of certain officers. It details the departure of the Chief Medical Officer and her new consulting agreement. There is no financial data or report attached, nor is this an earnings release or annual report. The document is focused on management changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is 3883 characters, which is typical for an 8-K filing of this nature and not a full report. Confidence is high due to the clear Item 5.02 heading and content about officer departure and appointment.
2019-06-06 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes information about the availability of proxy materials for the Annual Meeting of Shareholders, including the Notice of Annual Meeting, Proxy Statement, and Annual Report on Form 10-K. The document is titled 'Important Notice Regarding the Availability of Proxy Materials' and provides instructions on how to access and vote on proxy materials. It does not contain the full proxy statement or detailed voting materials but serves as a notice to shareholders about the proxy materials and the meeting. Given the document length is 4065 characters and it primarily announces the availability of proxy materials and voting instructions, it fits the category of Proxy Solicitation & Information Statement (PSI).
2019-05-10 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.